WHAT:
| Poster 166:
Efficacy and Tolerability of Tapentadol Extended Release for Diabetic Peripheral Neuropathic Pain: Results of a Randomized-Withdrawal, Double-Blind, Placebo-Controlled Phase 3 Study.
Lead author: Mila S. Etropolski, M.D. | |
Poster 125:
Dose Stability of Tapentadol Extended Release for the Relief of Moderate to Severe Chronic Osteoarthritis Knee Pain. Lead author: Kathleen Kelly, M.D. | ||
Poster 112:
Dose Equivalence and Direct Conversion Between Tapentadol Immediate Release and Tapentadol Extended Release for Moderate to Severe Chronic Low Back Pain. Lead author: Mila S. Etropolski, M.D. | ||
WHEN:
| Wednesday, February 3 from 5:00 to 6:30 p.m. central time (CT) and Thursday, February 4 from 6:00 to 7:00 p.m. CT | |
WHERE: | Exhibit Hall B of the Henry B. Gonzalez Convention Center in San Antonio, TX | |
